Eli Lilly and Company

Applied Molecular Evolution

Catherine Brautigam Beidler

Kristine Kay Kikly

Derrick Ryan Witcher

Beth Ann Strifler

Stuart W Bright

Chetankumar Natvarlal Patel

Daniel Scott Girard

Alain Philippe Vasserot

Michael Parvin Johnson

Jeffry Dean Watkins

David Matthew Marquis

Craig Duane Dickinson

Rohn Lee Millican, Jr

Neungseon Seo

Jeffrey Streetman Boyles

Josef George Heuer

Songqing Na

Sudhakar Reddy Chintharlapalli

Ramona Judita Petrovan

Stuart Willis Bright

Derek Ryan Witcher

Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.

Anti-PACAP antibody

Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

Pan-ELR+ CXC chemokine antibodies

Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.

Anti-TrkA antibody

Antibodies are provided that specifically bind seven human ELRCXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

[object Object]

Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNF&#x3b1;) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNF&#x3b1; and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.

Anti-TNF-/anti-IL-23 bispecific antibodies

The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.

Nucleic acids encoding antibodies that bind IL-23

Pan-ELR+ CXC Chemokine Antibodies

Antibodies that bind to IL-23

The present invention provides antibodies that bind human TGF-alpha and human Epiregulin and are characterized as having high affinity, selective, and strong neutralizing properties. The antibodies are useful in the treatment of diabetic nephropathy.

Antibodies that bind TGF-alpha and epiregulin

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.

Anti-IL-23 antibodies

The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.

Growing community of inventors

Poway, CA, United States of America

Catherine Brautigam Beidler